Genetic Variation Predicting Cisplatin Cytotoxicity Associated with Overall Survival in Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Purpose: Inherited variability in the prognosis of lung cancer patients treated with platinum-based chemotherapy has been widely investigated. However, the overall contribution of genetic variation to platinum response is not well established. To identify novel candidate single nucleotide polymorphisms (SNP)/genes, we carried out a genome-wide association study (GWAS) for cisplatin cytotoxicity by using lymphoblastoid cell lines (LCL), followed by an association study of selected SNPs from the GWAS with overall survival (OS) in lung cancer patients. Experimental Design: A GWAS for cisplatin was conducted with 283 ethnically diverse LCLs. A total of 168 top SNPs were genotyped in 222 small cell lung cancer (SCLC) and 961 non-SCLC (NSCLC) patients treated with platinum-based therapy. Association of the SNPs with OS was determined by using the Cox regression model. Selected candidate genes were functionally validated by siRNA knockdown in human lung cancer cells. Results: Among 157 successfully genotyped SNPs, 9 and 10 SNPs were top SNPs associated with OS for patients with NSCLC and SCLC, respectively, although they were not significant after adjusting for multiple testing. Fifteen genes, including 7 located within 200 kb up or downstream of the 4 top SNPs and 8 genes for which expression was correlated with 3 SNPs in LCLs were selected for siRNA screening. Knockdown of DAPK3 and METTL6, for which expression levels were correlated with the rs11169748 and rs2440915 SNPs, significantly decreased cisplatin sensitivity in lung cancer cells. Conclusions: This series of clinical and complementary laboratory-based functional studies identified several candidate genes/SNPs that might help predict treatment outcomes for platinum-based therapy of lung cancer. Clin Cancer Res; 17(17); 5801–11. ©2011 AACR.

[1]  Jing Wu,et al.  Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2011, Lung cancer.

[2]  Yi Shi,et al.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis , 2011, Medical oncology.

[3]  G. Abecasis,et al.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes , 2010, Genetic epidemiology.

[4]  J. Yokota,et al.  Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Krishna R. Kalari,et al.  Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. , 2010, Genome research.

[6]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[7]  Hong-yan Cheng,et al.  Association Between Polymorphisms of ERCC1 and XPD and Clinical Response to Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer , 2010, American journal of clinical oncology.

[8]  Patrick F. Sullivan,et al.  A quality control algorithm for filtering SNPs in genome-wide association studies , 2010, Bioinform..

[9]  D. Schaid,et al.  Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[10]  Krishna R. Kalari,et al.  Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers , 2009, PloS one.

[11]  Xinchen Sun,et al.  Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. , 2009, Lung cancer.

[12]  M. Dolan,et al.  Role of copper transporters in resistance to platinating agents , 2009, Cancer Chemotherapy and Pharmacology.

[13]  S. Duan,et al.  Whole-genome approach implicates CD44 in cellular resistance to carboplatin , 2009, Human Genomics.

[14]  E. Shin,et al.  Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Rivas,et al.  Genetic Analysis of Human Traits In Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines , 2008, PLoS genetics.

[16]  Joe Y. Chang,et al.  Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy , 2008, Pharmacogenetics and genomics.

[17]  Krishna R. Kalari,et al.  Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. , 2008, Cancer research.

[18]  Shiwei Duan,et al.  Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans , 2008, Molecular Cancer Therapeutics.

[19]  W. Bamlet,et al.  Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. , 2008, Archives of internal medicine.

[20]  H. Stefánsson,et al.  Genetics of gene expression and its effect on disease , 2008, Nature.

[21]  E. Giovannetti,et al.  Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.

[22]  S. Duan,et al.  Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis , 2008, Pharmacogenetics and genomics.

[23]  T. Eisen,et al.  Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. , 2007, Human molecular genetics.

[24]  S. Pietrokovski,et al.  ZIPK: A Unique Case of Murine-Specific Divergence of a Conserved Vertebrate Gene , 2007, PLoS genetics.

[25]  Shiwei Duan,et al.  Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. , 2007, American journal of human genetics.

[26]  Simon C. Potter,et al.  Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls , 2007, Nature.

[27]  D. Schaid,et al.  Exact tests of Hardy-Weinberg equilibrium and homogeneity of disequilibrium across strata. , 2006, American journal of human genetics.

[28]  T. Ward,et al.  Glutathione-S-Transferase P1 Isoenzyme Polymorphisms, Platinum-Based Chemotherapy, and Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[30]  Joe Y. Chang,et al.  Association between glutathione S‐transferase π polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma , 2006, Cancer.

[31]  R. Rosell,et al.  14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Melton,et al.  α1-Antitrypsin and Neutrophil Elastase Imbalance and Lung Cancer Risk , 2005 .

[33]  G. Abecasis,et al.  A note on exact tests of Hardy-Weinberg equilibrium. , 2005, American journal of human genetics.

[34]  C. Molony,et al.  Genetic analysis of genome-wide variation in human gene expression , 2004, Nature.

[35]  D. Neuberg,et al.  Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy , 2004, Clinical Cancer Research.

[36]  A. Kimchi,et al.  DAP-kinase as a target for drug design in cancer and diseases associated with accelerated cell death. , 2004, Seminars in cancer biology.

[37]  D. Neuberg,et al.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Cook,et al.  Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity , 2004, Cancer Research.

[39]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[40]  Ruey-Hwa Chen,et al.  DAP-kinase induces apoptosis by suppressing integrin activity and disrupting matrix survival signals , 2002, The Journal of cell biology.

[41]  A. Kimchi,et al.  DAP kinase-a proapoptotic gene that functions as a tumor suppressor. , 2001, Experimental cell research.

[42]  T. Lesnick,et al.  Alpha1-antitrypsin deficiency allele carriers among lung cancer patients. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[43]  Shizuo Akira,et al.  ZIP Kinase, a Novel Serine/Threonine Kinase Which Mediates Apoptosis , 1998, Molecular and Cellular Biology.

[44]  M. Ratain,et al.  Pharmacogenetics and pharmacogenomics of anticancer agents , 2009, CA: a cancer journal for clinicians.

[45]  R. Altman,et al.  Platinum pathway. , 2009, Pharmacogenetics and genomics.

[46]  K. Mossman.  The Wellcome Trust Case Control Consortium, U.K. , 2008 .

[47]  E. Giovannetti,et al.  Correlation of cytidine deaminase (CDA), xeroderma pigmentosum group D (XPD) and excision repair cross-complementing 1 (ERCC1) genes single nucleotide polymorphisms (SNPS) with response and survival in gemcitabine/cisplatin treated advanced non-small-cell lung cancer (NSCLC) patients , 2007 .

[48]  L. Melton,et al.  Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. , 2005, Chest.

[49]  Alfred A. Bartolucci,et al.  Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1996 .

[50]  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. , 1995, BMJ.